ExoLuminate Study for Early Detection of Pancreatic Cancer
Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients
Biological Dynamics
1,000 participants
Dec 19, 2022
OBSERVATIONAL
Conditions
Summary
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
Eligibility
Inclusion Criteria4
- ≥18 years old.
- Meeting criteria for one of the study cohorts.
- Capable of giving informed consent.
- Able to provide a blood sample.
Exclusion Criteria6
- \< 18 years old.
- Pregnancy.
- Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
- Prior organ transplant or bone marrow transplant.
- History of fainting or other adverse effects when blood is drawn.
- Any condition that, in the opinion of the investigator, should preclude enrollment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05625529